Open Journal Systems

Cover Image

Thiazoles as Imperative Molecules for Potential Therapeutic Importance

Pratip Kashinath Chaskar, Swapnil Chaudhari

Abstract


This article outlines the biological significance of one of the most important heterocycles, the thiazoles. An attempt has been made to cover most of the physiologically as well as medicinally important compounds containing thiazole derivatives.

Full Text:

PDF

References


LeVine III H, 1999. Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods in Enzymology 309: 274-284.

http://dx.doi.org/10.1016/S0076-6879(99)09020-5

Hastings JW, 1996. Chemistries and colors of bioluminescent reactions, a review. Gene, 173: 5-11.

http://dx.doi.org/10.1016/0378-1119(95)00676-1

Hastings JW, 1982. Biological diversity, chemical mechanisms, and the evolutionary origins of bioluminescent systems. Journal of Molecular Evolution 19: 309-321.

http://dx.doi.org/10.1007/BF02101634

Bettendorff L, B Wirtzfeld, AF Makarchikov, G Mazzucchelli, M Frederich, T Gigliobianco, M Gangolf, E DePauw, L Angenot, and P Wins, 2007. Discovery of a natural thiamine adenine nucleotide. Nature Chemical Biology 3: 211-212.

http://dx.doi.org/10.1038/nchembio867

PMid:17334376

Song JH, CS Huang, K Nagata, JZ Yeh, and T Narahashi, 1997. Differential Action of Riluzole on Tetrodotoxin-Sensitive and Tetrodotoxin-Resistant Sodium Channels. Journal of Pharmacology and Experimental Therapeutics 282: 707-714.

PMid:9262334

Wokke J, 1996. Riluzole. Lancet, 348: 795-799.

http://dx.doi.org/10.1016/S0140-6736(96)03181-9

Azbill RD, X Mu, and JE Springer, 2000. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Research 871: 175-180.

http://dx.doi.org/10.1016/S0006-8993(00)02430-6

Dunlop J, H BealMcIlvain, Y She, and DS Howland, 2003. Impaired Spinal Cord Glutamate Transport Capacity and Reduced Sensitivity to Riluzole in a Transgenic Superoxide Dismutase Mutant Rat Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience 23: 1688-1696.

PMid:12629173

Upadhyay MP, EP West, and AP Sharma, 1980. Keratitis due to Aspergillus flavus successfully treated with thiabendazole. British Journal of Ophthalmology 64: 30-32.

http://dx.doi.org/10.1136/bjo.64.1.30

PMid:6766732 PMCid:PMC1039343

Igual-Adell R, C Oltra-Alcaraz, E Soler-Company, P Sanchez-Sanchez, J Matogo-Oyana, and D Rodríguez-Calabuig, 2004. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opinion on Pharmacotherapy 5: 2615-2619.

http://dx.doi.org/10.1517/14656566.5.12.2615

PMid:15571478

Portugal R, R Schaffel, L Almeida, N Spector, and M Nucci, 2002. Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases, a randomized double-blind placebo-controlled study. Haematologica 87: 663-664.

PMid:12031927

Hepworth W, and GJ Stacey, 1970. Aryl-thiazolyl-acetic acid derivatives. U.S. Patent 3538107.

Noble S, and JA Balfour, 1996. Meloxicam. Drugs 51: 424-430.

http://dx.doi.org/10.2165/00003495-199651030-00007

PMid:8882380

Bittencourt PR, and A Richens, 1981. Anticonvulsant-Induced Status Epilepticus in Lennox-Gastaut Syndrome. Epilepsia 22: 129-134.

http://dx.doi.org/10.1111/j.1528-1157.1981.tb04339.x

PMid:6781886

Reith DM, J Fountain, R McDowell, and M Tilyard, 2003. Comparison of the Fatal Toxicity Index of Zopiclone with Benzodiazepines. Journal of Toxicology - Clinical Toxicology 41: 975-980.

http://dx.doi.org/10.1081/CLT-120026520

PMid:14705844

Shinya K, K Wierzba, K Matsuo, T Ohtani, Y Yamada, K Furihata, Y Hayakawa, and HJ Seto, 2001. Telomestatin, a Novel Telomerase Inhibitor from Streptomyces anulatus. American Chemical Society 123: 1262-1263.

Goodin S, 2008. Novel cytotoxic agents, Epothilones. American Journal of Health-System Pharmacy 65: S10-S15.

http://dx.doi.org/10.2146/ajhp080089

PMid:18463327

Lee FY, R Borzilleri, CR Fairchild, A Kamath, R Smykla R Kramer and G Vite 2008. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemotherapy and Pharmacology 63: 157-166.

http://dx.doi.org/10.1007/s00280-008-0724-8

PMid:18347795

Thomas ES, HL Gomez, RK Li, HC Chung, LE Fein, VF Chan, J Jassem, XB Pivot JV Klimovsky, F Mendoza, B Xu, M Campone, GL Lerzo, RA Peck, P Mukhopadhyay, LT Vahdat, HH Roche 2007. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology 25: 5210-5217.

http://dx.doi.org/10.1200/JCO.2007.12.6557

PMid:17968020

Aghajanian C, HA Burris, S Jones, DR Spriggs, MB Cohen, R Peck, P Sabbatini, ML Hensley, FA Greco, J Dupont, and OA O'Connor 2007. Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in Patients with Advanced Solid Tumors and Lymphomas. Journal of Clinical Oncology 25: 1082-1088.

http://dx.doi.org/10.1200/JCO.2006.08.7304

PMid:17261851

Rosenberg S, VT DeVita, and S Hellman, 2005. Cancer: Principles & Practice of Oncology Hagerstwon, M. D.: Lippincott Williams & Wilkins.

Das J, P Chen, D Norris, R Padmanabha, J Lin, RV Moquin, Z Shen, LS Cook, AM Doweyko, S Pitt, S Pang, DR Shen, Q Fang, HF Fex, KW McIntyre, DJ Shuster, KM Gillooly, K Behnia, GL Schieven, J Wityak, and JC Barrish 2006. 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazol-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor. Journal of Medicinal Chemistry 49: 6819-6832.

http://dx.doi.org/10.1021/jm060727j

PMid:17154512

Eriks JC, GH Vander GJ Sterk, and H Timmerman, 1992. Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles. Journal of Medicinal Chemistry 35: 3239-3246.

http://dx.doi.org/10.1021/jm00095a021

PMid:1507209

Coruzzi G, H Timmerman, M Adami, and G Bertaccini, 1998. The new potent and selective histamine H2 receptor agonist amthamine as a tool to study gastric secretion. Naunyn-Schmiedeberg's Archives of Pharmacology 348: 77-81.

http://dx.doi.org/10.1007/BF00168540

Ezeamuzie CI, and E Philips, 2000. Histamine H2 receptors mediate the inhibitory effect of histamine on human eosinophil degranulation. British Journal of Pharmacology 131: 482-488.

http://dx.doi.org/10.1038/sj.bjp.0703556

PMid:11015298 PMCid:PMC1572337

Fernandez N, F Monczor, A Baldi, C Davio, and C. Shayo, 2008. Histamine H2 Receptor Trafficking, Role of Arrestin, Dynamin, and Clathrin in Histamine H2 Receptor Internalization. Molecular Pharmacology 74: 1109-1118.

http://dx.doi.org/10.1124/mol.108.045336

PMid:18617631

Threlfell S, R Exley, SJ Cragg, and SA Greenfield, 2008. Constitutive histamine H2 receptor activity regulates serotonin release in the substantia nigra. Journal of Neurochemistry 107: 745-755.

http://dx.doi.org/10.1111/j.1471-4159.2008.05646.x

PMid:18761715

Humphries TJ, and GJ Merritt, 1999. Review article, drug interactions with agents used to treat acid-related diseases. Alimentary Pharmacology & Therapeutics 13: 18-26.

http://dx.doi.org/10.1046/j.1365-2036.1999.00021.x

PMid:10491725

Patel SS, and MI Wilde, 1996. Ebrotidine. Drugs, 51: 974-980.

http://dx.doi.org/10.2165/00003495-199651060-00006

PMid:8736619

Atmaca M, M Kuloglu, E Tezcan, B Ustundag, and N Kilic, 2004. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human Psychopharmacology: Clinical and Experimental 19: 37-40.

http://dx.doi.org/10.1002/hup.477

PMid:14716710

Worlock A, 1956. Barbiturate Poisoning Treated with Amiphenazole and Bemegride. British Medical Journal 2: 1099-1107.

http://dx.doi.org/10.1136/bmj.2.5001.1099

PMid:13364395 PMCid:PMC2035840

Mears GW, 1958. Massive Doses of Bemegride and Amiphennzole in Treatment of Barbiturate Poisoning. British Medical Journal 1: 757-758.

http://dx.doi.org/10.1136/bmj.1.5073.757

PMid:13510792 PMCid:PMC2028148

Dotevall G, and B Herner, 1957. Treatment of Acute Primidone Poisoning with Bemegride and Amiphenazole. British Medical Journal 2: 451-452.

http://dx.doi.org/10.1136/bmj.2.5042.451

PMid:13446511 PMCid:PMC1961943

Rowell NR, 1957. Treatment of Glutethimide Poisoning. Lancet, 272: 407-409.

http://dx.doi.org/10.1016/S0140-6736(57)90466-X

Little GM, 1962. Use of Amiphenazole in Respiratory Failure. British Medical Journal 1: 223-226.

http://dx.doi.org/10.1136/bmj.1.5273.223

PMid:14465883 PMCid:PMC1957266

McKeogh J, and FH Shaw, 1956. Further Experience with Amiphenazole and Morphine in Intractable Pain. British Medical Journal 1: 142-144.

http://dx.doi.org/10.1136/bmj.1.4959.142

PMid:13276651 PMCid:PMC1978927

Gershon S, DW Bruce, N Orchard, and FH Shaw, 1958. Amiphenazole and Morphine in Production of Analgesia. British Medical Journal 2: 366-368.

http://dx.doi.org/10.1136/bmj.2.5092.366

PMid:13560868 PMCid:PMC2025982

Gairola RL, PK Gupta, and K Pandley, 1980. Antagonists of morphine-induced respiratory depression, a study in postoperative patients. Anaesthesia, 35: 17-21.

http://dx.doi.org/10.1111/j.1365-2044.1980.tb03714.x

PMid:6994518

Zhao J, V Golozoubova, B Cannon, J Nedergaard, and J Can. 2001. Arotinolol is a weak partial agonist on β3-adrenergic receptors in brown adipocytes. Physiology. Pharmacology 79: 585-593.

Huang C, B Dong, Y Zhang, H Wu, Q Liu, and JH Flaherty 2009. Cognitive impairment and hypertension among Chinese nonagenarians and centenarians. Hypertension Research 32: 554-558.

http://dx.doi.org/10.1038/hr.2009.72

PMid:19478816

Lee KS, JS Kim, JW Kim, WY Lee, BS Jeon, and D Kim, 2003. A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism & Related Disorders 9: 341-347.

http://dx.doi.org/10.1016/S1353-8020(03)00029-4

Hazen R, R Harvey, R Ferris, C Craig, P Yates, P Griffin, J Miller, I Kaldor, J Ray, V Samano, E Furfine, A Spaltenstein, M Hale, R Tung, M Clair, M Hanlon, and L Boone 2007. In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrobial Agents and Chemotherapy 51: 3147-3154.

http://dx.doi.org/10.1128/AAC.00401-07

PMid:17620375 PMCid:PMC2043237

DeBattista C, HB Solvason, JA Breen, and AF Schatzberg, 2000. Pramipexole Augmentation of a Selective Serotonin Reuptake Inhibitor in the Treatment of Depression. Journal of Clinical Psychopharmacology 20: 274-275.

http://dx.doi.org/10.1097/00004714-200004000-00029

PMid:10770475

Lattanzi L, L DellOsso, P Cassano, S Pini, P Rucci, PR Houck, A Gemignani, G Battistini, A Bassi, M Abelli, and GB Cassano, 2002. Pramipexole in treatment-resistant depression, a 16-week naturalistic study. Bipolar Disorders 4: 307-314.

http://dx.doi.org/10.1034/j.1399-5618.2002.01171.x

PMid:12479663

Cassano P, L Lattanzi, F Soldani, S Navari, G Battistini, A Gemignani, and GB Cassano, 2004. Pramipexole in treatment-resistant depression, an extended follow-up. Depress Anxiety, 20: 131-138.

http://dx.doi.org/10.1002/da.20038

PMid:15549689

Holman AJ, and RR Myers, 2005. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis & Rheumatism 52: 2495-2505.

http://dx.doi.org/10.1002/art.21191

PMid:16052595

Stamp LK, JL O'Donnell, and PT Chapman, 2007. Wegener's granulomatosis in New Zealand, evidence for a latitude-dependent incidence gradient. Internal Medicine Journal 37: 258-266.

http://dx.doi.org/10.1111/j.1445-5994.2007.01315.x

PMid:17388867

Becker MA, HR Schumacher, RL Wortmann, RC Owens, SV Kazakova, SP Sambol, S Johnson, DN Gerding, 2005. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. The New England Journal of Medicine 353: 2450-2461.

http://dx.doi.org/10.1056/NEJMoa050373

PMid:16339094

Cosford ND, L Tehrani, J Roppe, E Schweiger, ND Smith, J Anderson, L Bristow, J Brodkin, X Jiang, I McDonald, S Rao, M Washburn, and MA Varney 2003. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine, A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity. Journal of Medicinal Chemistry 46: 204-206.

http://dx.doi.org/10.1021/jm025570j

PMid:12519057

Lea PM, and AI Faden, 2006. Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP. CNS Drug Reviews 12: 149-166.

http://dx.doi.org/10.1111/j.1527-3458.2006.00149.x

PMid:16958988

Lea PM, VA Movsesyan, and AI Faden, 2005. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. British Journal of Pharmacology 145: 527-534.

http://dx.doi.org/10.1038/sj.bjp.0706219

PMid:15821750 PMCid:PMC1576169

Palucha A, P Branski, B Szewczyk, JM Wieronska, K Klak, and A Pilc, 2005. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacology Biochemistry and Behavior 81: 901-906.

http://dx.doi.org/10.1016/j.pbb.2005.06.015

PMid:16040106

Zhu CZ, SG Wilson, JP Mikusa, CT Wismer, DM Gauvin, JJ Lynch, CL Wade, MW Decker, and P Honore, 2004. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. European Journal of Pharmacology 506: 107-118.

http://dx.doi.org/10.1016/j.ejphar.2004.11.005

PMid:15588730

Varty GB, M Grilli, A Forlani, S Fredduzzi, ME Grzelak, DH Guthrie, RA Hodgson, SX Lu, E Nicolussi, AJ Pond, EM Parker, JC Hunter, GA Higgins, A Reggiani, and R Bertorelli, 2005. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents, a comparison of efficacy and side-effect profiles. Psychopharmacology 179: 207-217.

http://dx.doi.org/10.1007/s00213-005-2143-4

PMid:15682298

Klodzinska A, E Tatarczynska, E Chojnacka-Wojcik, G Nowak, ND Cosford, and A Pilc, 2004. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology 47: 342-350.

http://dx.doi.org/10.1016/j.neuropharm.2004.04.013

PMid:15275823

Cowen MS, E Djouma, and AJ Lawrence, 2005. The Metabotropic Glutamate 5 Receptor Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine Reduces Ethanol Self-Administration in Multiple Strains of Alcohol-Preferring Rats and Regulates Olfactory Glutamatergic Systems. Journal of Pharmacology and Experimental Therapeutics 315: 590-600.

http://dx.doi.org/10.1124/jpet.105.090449

PMid:16014750

Dravolina OA, W Danysz, and AY Bespalov, 2006. Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats, Psychopharmacology 187: 397-404.

http://dx.doi.org/10.1007/s00213-006-0440-1

PMid:16896963

Barclay L, 2007. Medscape Medical News (Accessed on March 16, 2013).

Knackstedt LA, R. I., Melendez, and P. W. Kalivas, 2009. Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine Seeking. Biol. Psychiatry, 67: 81-84.

http://dx.doi.org/10.1016/j.biopsych.2009.07.018

PMid:19717140 PMCid:PMC2795043

White NJ, 2003. Melioidosis. Lancet, 361: 1715-1722.

http://dx.doi.org/10.1016/S0140-6736(03)13374-0

Ollef MH, 2009. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Critical Care & Resuscitation 11: 282-286.

Kanafani ZA, and GR Corey, 2009. Ceftaroline, a cephalosporin with expanded Gram-positive activity. Future Microbiology 4: 25-33.

http://dx.doi.org/10.2217/17460913.4.1.25

PMid:19207097

Parish D, and N Scheinfeld, 2008. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Current Opinion in Investigational Drugs 9: 201-209.

PMid:18246523

Yahav D, M Paul, A Fraser, N Sarid, and L Leibovici, 2007. Efficacy and safety of cefepime, a systematic review and meta-analysis. The Lancet Infectious Diseases 7: 338-348.

http://dx.doi.org/10.1016/S1473-3099(07)70109-3

Chapman TM, and CM Perry, 2003. A Review of its Use in the Management of Hospitalized Patients with Pneumonia. American Journal of Respiratory Medicine 2: 75-107.

http://dx.doi.org/10.1007/BF03256641

PMid:14720024

McMillan A, and H Young, 2007. The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime. International Journal of STD & AIDS 18: 253-254.

http://dx.doi.org/10.1258/095646207780658971

PMid:17509176

Adam D, U Hostalek, and K Troster, 1995. 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis, Comparison with 10-day penicillin V therapy, Infection, 23: S83-S86.

http://dx.doi.org/10.1007/BF01742990

PMid:8537138




DOI: http://dx.doi.org/10.14259%2Fbmc.v1i1.4

Refbacks

  • There are currently no refbacks.